Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.

Kaseb, Ahmed O; Garrett-Mayer, E; Morris, J S; Xiao, L; Lin, E; Onicescu, G; Hassan, M M; Hassabo, H M; Iwasaki, M; Deaton, F L; Abbruzzese, J L; Thomas, M B

Kaseb, Ahmed O; Garrett-Mayer, E; Morris, J S; Xiao, L; Lin, E; Onicescu, G; Hassan, M M; Hassabo, H M; Iwasaki, M; Deaton, F L; Abbruzzese, J L; Thomas, M B.

Affiliation

Kaseb AO; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. akaseb@mdanderson.org

Oncology ; 82(2): 67-74, 2012.

Article in En | MEDLINE | ID: mdl-22327795

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Angiopoietin-2/blood; Antibodies, Monoclonal, Humanized/administration & dosage; Antibodies, Monoclonal, Humanized/adverse effects; Bevacizumab; Carcinoma, Hepatocellular/mortality; Disease-Free Survival; ErbB Receptors/blood; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms/mortality; Male; Middle Aged; Proportional Hazards Models; Quinazolines/administration & dosage; Quinazolines/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Oncology Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google